Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial

Delphine Bertrand; Johan Joly; Barbara Neerinckx; Patrick Durez; Jan Lenaerts; Rik Joos; Kristof Thevissen; Tom Zwaenepoel; J. Vanhoof; Silvana Di Romana; V. Taelman; E. Van Essche; Luk Corluy; Clio Ribbens; M. Vanden Berghe; Mieke Devinck; Sofia Ajeganova; Anne Durnez; Y. Boutsen; J. Margaux; Isabelle Peene; Jan Van Offel; Michaël Doumen; Sofia Pazmiño; Elias De Meyst; Myroslava Kulyk; Nelly Creten; René Westhovens; Patrick Verschueren

doi:10.1136/rmdopen-2024-004535

Abstract

To investigate if patients with early rheumatoid arthritis responding insufficiently to initial methotrexate (MTX) and bridging glucocorticoids (GCs) could benefit from early but temporary etanercept introduction as a second remission-induction attempt.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bertrand et al. (2024) studied this question.

synapsesocial.com/papers/68e5e1d3b6db64358757642b https://doi.org/10.1136/rmdopen-2024-004535

View Full Paper

Ask AI

Bookmark

Share

Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial

Abstract

Discussion

Cite This Study

Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading